Michał Mazurkiewicz

Michał Mazurkiewicz

Auto-generated profile, based on publicly available information

Michał Mazurkiewicz

Department of Pulmonology, Allergology and Respiratory Oncology, Poznan University of Medical Sciences, Poznan, Poland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2024 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
MDMagdalena Durda-Masny
Magdalena Durda-Masny
JGJoanna Goździk-Spychalska
Joanna Goździk-Spychalska
KMKatarzyna Morańska
Katarzyna Morańska
NPNatalia Pawłowska
Natalia Pawłowska
MMMichał Mazurkiewicz
Michał Mazurkiewicz
ASAnita Szwed
Anita Szwed
Microbial dysbiosis has been linked to cystic fibrosis (CF); however, the composition of gut microbiota in adult CF patients in relation to severity of CF transmembrane conductance regulator (CFTR) gene mutation and nutritional status have not yet been explored. Study aimed to assess the gut microbiota composition in adults with CF, and its relationship with the severity of CFTR mutations, and BMI. Gut microbiota of 41 adults with CF, and 26 non-CF controls were compared using whole 16S rRNA gene sequencing. Differences in the microbial community between groups of patients classified according to the severity of CFTR mutations, and BMI were assessed. The alpha diversity, beta diversity, and taxa abundance were identified to reflect gut microbiota composition. Results showed a significant decrease in alpha diversity of bacterial communities in CF compared to non-CF group, but no significant difference between the CF groups distinguished by the severity of CFTR mutations. However, more severe mutations were associated with the higher relative abundance of Bacteroides and Streptococcus and the lower relative abundance of Faecalibacterium and Blautia. Undernourished CF patients showed significantly lower alpha diversity compared to non-CF group and CF patients with BMI within the norm. Significant differences in the structure of the gut microbiota between CF and non-CF groups, as well as between BMI groups were also found. Our research indicates that CF is associated with alterations in gut microbiota in adults. Additionally, in adult CF patients, the composition of the gut microbiota is also related to BMI.

1 September 2023 in Clinical Interventions in Aging
Verified
Journal Article
Open access
PDF file
MMMichal Mazurkiewicz
Michal Mazurkiewicz
WLWojciech Lizurej
Wojciech Lizurej
ŁMŁukasz Mazurkiewicz
Łukasz Mazurkiewicz
AMArkadiusz Majewski
Arkadiusz Majewski
STSlawomir Tobis
Slawomir Tobis
MCMaciej Cymerys
Maciej Cymerys
Purpose: The admissions of nonagenarians to internal medicine wards are rising. The aim of this study was to analyse the causes of ward admission and blood and renal parameters as potential mortality predictors in this age group. Patients and Methods: Out of 1140 patients, 111 nonagenarians aged 90+ admitted to the Internal Medicine Ward in one general hospital in Poznan in 2019 were studied. Medical records of these patients were analysed to find factors attributable to the hospitalisation. Results: The leading causes of admission were infections and cardiovascular diseases, and the main causes of death were cardiovascular diseases. Elevated C-reactive protein (CRP) level was a statistically significant death predictor. Equally, decreased albumin level was found to be a mortality predictor. No such relationships were obtained for haematological or renal parameters. Conclusion: Our study uniquely analysed a relatively large group of hospitalised nonagenarians and identified those who need particular attention in the ward by identifying those with the highest risk of death. CRP and albumin levels may serve as useful indicators of in-hospital mortality in this age group.

29 August 2025 in Aktualności Neurologiczne
Verified
Journal Article
Open access
PDF file
MMMichał Andrzej Mazurkiewicz
Michał Andrzej Mazurkiewicz
ISIwona Sylwia Skrzypczak
Iwona Sylwia Skrzypczak
Neurosarcoidosis is an inflammatory disease of unknown aetiology, characterised by the presence of non-caseating granulomas within the nervous system. Its prevalence in patients diagnosed with sarcoidosis is estimated to be approximately 10%. The clinical presentation is ambiguous, with symptoms that may manifest acutely or progress gradually over time. Many of these symptoms mimic those of other diseases, making neurosarcoidosis a diagnostic challenge. No sufficiently sensitive or specific biomarkers are available to enable an accurate diagnosis. A range of diagnostic tests must be performed to exclude other conditions. Histopathological confirmation via biopsy is necessary to make a definitive diagnosis, which is not always possible due to the location of lesions and the potential risk of complications associated with performing a biopsy. Once a diagnosis is established, regular follow-up examinations are necessary to monitor disease activity and assess the progression of changes. The optimal treatment strategy depends on the patient’s current clinical status and the potential risk of side effects. Three main lines of treatment for neurosarcoidosis have been described. Treatment selection should also take into account the ability of medications to cross the blood–brain barrier. Treatment response, severity of the disease at the time of diagnosis, and lesion location within the nervous system all influence the prognosis. With appropriate treatment, the majority of patients achieve either complete or partial remission. Therefore, neurosarcoidosis requires multidisciplinary specialist care and a comprehensive approach to each patient.

17 December 2021
Verified
Book Chapter
Closed access
PDF file
MMMichał Mazurkiewicz
Michał Mazurkiewicz
"Mascots" published on Dec 2021 by Edward Elgar Publishing.